Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs

Fernando J. Bravo, Nigel Bourne, Christopher J. Harrison, Chitra Mani, Lawrence R. Stanberry, Martin G. Myers, David I. Bernstein

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Neonatal herpes simplex virus (HSV) infection produces severe disease with unacceptable morbidity and mortality with current antiviral therapies. The effect of therapy with passive anti-HSV antibody and acyclovir was evaluated using a guinea pig model of neonatal HSV. Newborn animals were inoculated intranasally and treated with acyclovir (60 mg/kg/day) or antibody (or both), beginning on days 0, 2, or 3 after HSV-2 inoculation. Acyclovir alone was effective only when begun on day 0, and antibody alone was effective when begun on or before day 2. Only combination therapy was effective on day 3, reducing mortality from 82% (14/17) in controls to 44% (7/16; P < .05). Combined therapy also significantly reduced the duration of skin, eye, and mouth disease and respiratory symptoms but not recurrent disease. These data suggest that addition of antibody therapy to acyclovir may improve the outcome of neonatal HSV disease.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalJournal of Infectious Diseases
Volume173
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Acyclovir
Guinea Pigs
Simplexvirus
Antibodies
Mouth Diseases
Newborn Animals
Therapeutics
Human Herpesvirus 2
Mortality
Eye Diseases
Virus Diseases
Skin Diseases
Antiviral Agents
Neonatal herpes
Morbidity

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Bravo, F. J., Bourne, N., Harrison, C. J., Mani, C., Stanberry, L. R., Myers, M. G., & Bernstein, D. I. (1996). Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. Journal of Infectious Diseases, 173(1), 1-6.

Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. / Bravo, Fernando J.; Bourne, Nigel; Harrison, Christopher J.; Mani, Chitra; Stanberry, Lawrence R.; Myers, Martin G.; Bernstein, David I.

In: Journal of Infectious Diseases, Vol. 173, No. 1, 1996, p. 1-6.

Research output: Contribution to journalArticle

Bravo, FJ, Bourne, N, Harrison, CJ, Mani, C, Stanberry, LR, Myers, MG & Bernstein, DI 1996, 'Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs', Journal of Infectious Diseases, vol. 173, no. 1, pp. 1-6.
Bravo, Fernando J. ; Bourne, Nigel ; Harrison, Christopher J. ; Mani, Chitra ; Stanberry, Lawrence R. ; Myers, Martin G. ; Bernstein, David I. / Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. In: Journal of Infectious Diseases. 1996 ; Vol. 173, No. 1. pp. 1-6.
@article{2a5a0f2a73fc4f0788e794df1bce04f3,
title = "Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs",
abstract = "Neonatal herpes simplex virus (HSV) infection produces severe disease with unacceptable morbidity and mortality with current antiviral therapies. The effect of therapy with passive anti-HSV antibody and acyclovir was evaluated using a guinea pig model of neonatal HSV. Newborn animals were inoculated intranasally and treated with acyclovir (60 mg/kg/day) or antibody (or both), beginning on days 0, 2, or 3 after HSV-2 inoculation. Acyclovir alone was effective only when begun on day 0, and antibody alone was effective when begun on or before day 2. Only combination therapy was effective on day 3, reducing mortality from 82{\%} (14/17) in controls to 44{\%} (7/16; P < .05). Combined therapy also significantly reduced the duration of skin, eye, and mouth disease and respiratory symptoms but not recurrent disease. These data suggest that addition of antibody therapy to acyclovir may improve the outcome of neonatal HSV disease.",
author = "Bravo, {Fernando J.} and Nigel Bourne and Harrison, {Christopher J.} and Chitra Mani and Stanberry, {Lawrence R.} and Myers, {Martin G.} and Bernstein, {David I.}",
year = "1996",
language = "English (US)",
volume = "173",
pages = "1--6",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs

AU - Bravo, Fernando J.

AU - Bourne, Nigel

AU - Harrison, Christopher J.

AU - Mani, Chitra

AU - Stanberry, Lawrence R.

AU - Myers, Martin G.

AU - Bernstein, David I.

PY - 1996

Y1 - 1996

N2 - Neonatal herpes simplex virus (HSV) infection produces severe disease with unacceptable morbidity and mortality with current antiviral therapies. The effect of therapy with passive anti-HSV antibody and acyclovir was evaluated using a guinea pig model of neonatal HSV. Newborn animals were inoculated intranasally and treated with acyclovir (60 mg/kg/day) or antibody (or both), beginning on days 0, 2, or 3 after HSV-2 inoculation. Acyclovir alone was effective only when begun on day 0, and antibody alone was effective when begun on or before day 2. Only combination therapy was effective on day 3, reducing mortality from 82% (14/17) in controls to 44% (7/16; P < .05). Combined therapy also significantly reduced the duration of skin, eye, and mouth disease and respiratory symptoms but not recurrent disease. These data suggest that addition of antibody therapy to acyclovir may improve the outcome of neonatal HSV disease.

AB - Neonatal herpes simplex virus (HSV) infection produces severe disease with unacceptable morbidity and mortality with current antiviral therapies. The effect of therapy with passive anti-HSV antibody and acyclovir was evaluated using a guinea pig model of neonatal HSV. Newborn animals were inoculated intranasally and treated with acyclovir (60 mg/kg/day) or antibody (or both), beginning on days 0, 2, or 3 after HSV-2 inoculation. Acyclovir alone was effective only when begun on day 0, and antibody alone was effective when begun on or before day 2. Only combination therapy was effective on day 3, reducing mortality from 82% (14/17) in controls to 44% (7/16; P < .05). Combined therapy also significantly reduced the duration of skin, eye, and mouth disease and respiratory symptoms but not recurrent disease. These data suggest that addition of antibody therapy to acyclovir may improve the outcome of neonatal HSV disease.

UR - http://www.scopus.com/inward/record.url?scp=0030068281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030068281&partnerID=8YFLogxK

M3 - Article

VL - 173

SP - 1

EP - 6

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -